Внутрипузырные инъекции триамцинолона и гидродистензия мочевого пузыря в лечении больных с первичным синдромом болезненного мочевого пузыря.

Abstract

Introduction. Primary bladder pain syndrome (PBPS) is important in urology, due to its high prevalence, negative impact on the quality of life of patients, as well as the lack of effectiveness of existing treatment strategies. The aim of the study was to compare the effectiveness of hydrodistension of the bladder (HD) in combination with intravesical injections of triamcinolone in patients with non-ulcer forms of PBPS. Materials and Methods. In this study participated 68 women with PBPS in the age 38 to 74 years (mean 53.7±9.4 years) were treated and divided into two groups. Patients of the 1st group (n=35) underwent HD in combination with intravesical injections of triamcinolone (in 30 points, 4 mg in 0.5 ml of saline per point, total dose 120 mg). Patients of the 2nd group (n=33) underwent only HD. Treatment efficacy was assessed in 1 and 3 months after the procedure. Results and discussion. One month after treatment a positive effect was observed in 30 (85.7%) patients of the 1st group and 22 (66.7%) patients of the 2nd group. After 3 months of treatment in the 1st group the improvement compared to the baseline remained in 28 (80%) patients and in the 2nd group only in 5 (15.2%) patients. The severity of symptoms in patients of the 1st group during these periods was significantly less than before treatment and also than in patients of the 2nd group. Tolerability of treatment in patients of both groups was good, no side effects were observed in any case. Conclusion. The results of the study indicate the efficacy and good tolerability of the combination of HD and intravesical injections of triamcinolone in patients with non-ulcer forms of PBPS. The therapeutic effect of the combined use of HD and triamcinolone was more pronounced and prolonged than after performing only HD.